CLARITY Extension Study
Public ClinicalTrials.gov record NCT00641537. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects With Relapsing-Remitting Multiple Sclerosis Who Have Completed Trial 25643 (CLARITY)
Study identification
- NCT ID
- NCT00641537
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Enrollment
- 867 participants
Conditions and interventions
Conditions
Interventions
- Cladribine Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2008
- Primary completion
- Dec 30, 2011
- Completion
- Dec 30, 2011
- Last update posted
- Dec 6, 2020
2008 – 2011
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Boulder | Colorado | — | — |
| Research Site | Atlanta | Georgia | — | — |
| Research Site | Chicago | Illinois | — | — |
| Research Site | Northbrook | Illinois | — | — |
| Research Site | Baltimore | Maryland | — | — |
| Research Site | Ann Arbor | Michigan | — | — |
| Research Site | Henderson | Nevada | — | — |
| Research Site | Newark | New Jersey | — | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Durham | North Carolina | — | — |
| Research Site | Columbus | Ohio | — | — |
| Research Site | Oklahoma City | Oklahoma | — | — |
| Research Site | Tulsa | Oklahoma | — | — |
| Research Site | Medford | Oregon | — | — |
| Research Site | Seattle | Washington | — | — |
| Research Site | Tacoma | Washington | — | — |
| Research Site | Charleston | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 99 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00641537, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 6, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00641537 live on ClinicalTrials.gov.